ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS

ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments
                                   for ALS

PR Newswire

CAMBRIDGE, Mass., Dec. 6, 2013

Collaboration to Explore Recombinant Human-Derived Monoclonal Antibodies
Targeting Misfolded SOD1

CAMBRIDGE, Mass., Dec. 6, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy
Development Institute (ALS TDI), together with its wholly-owned subsidiary,
Anelixis Therapeutics, announced today that it has formed a research
partnership with Neurimmune to advance potential treatments for ALS, also
known as Lou Gehrig's disease. The research partnership will explore a human
monoclonal antibody that targets misfolded superoxide dismutase 1 (SOD1).
Misfolded SOD1 accumulates in familial and sporadic ALS, suggesting a
generalized role as a drug target for ALS treatments.


"We are excited by the results of Neurimmune's findings," says Steve Perrin,
Ph.D., CEO & CSO of ALS TDI. "Recent evidence would suggest that therapies
targeting misfolded SOD1 could be important in both sporadic and familial
forms of ALS. It is crucial that we use every tool available to us to advance
potential treatments toward the clinic, and we are proud to work together with
Neurimmune to attempt to do just that."

The collaboration will explore the high-affinity human antibodies developed by
Neurimmune that selectively target misfolded SOD1. In preclinical studies with
transgenic mice, chronic antibody treatment significantly reduced SOD1
pathology and rescued spinal cord motor neurons, resulting in significantly
reduced muscle atrophy, better motor functions and increased survival.
Neurimmune will present the key findings of their approach at the
International Symposium on ALS/MND Research in Milan, Italy on December 7,

"ALS is a devastating neuromuscular disease, and there is an urgent need for
new and effective therapiesthat can slow or stop its progression," says Jan
Grimm, Ph.D., CSO of Neurimmune. "Our human antibodies are directed against
pathologically misfolded SOD1 and the selected lead candidate shows marked
efficacy in independent ALS animal models. We believe that there is
significant potential for this therapeutic approach for ALS and are
enthusiastic to jointly advancing the program towards clinical development
together with ALS TDI."

About ALS Therapy Development Institute (ALS TDI)
The mission of the ALS Therapy Development Institute (ALS TDI) is to discover
and develop effective treatments to end ALS as soon as possible. ALS TDI is
the world's largest independent ALS/MND drug development-focused nonprofit
organization.It currently has partnerships with dozens of pharmaceutical and
biotechnology companies worldwide in order to advance potential treatments
into the clinic. Itslead ALS therapeutic candidate, Novartis' (Switzerland)
Gilenya (TDI-132), is in Phase 2A clinical trial for ALS, and the Institute
has a research agreement on a second candidate with Biogen Idec (USA) and UCB
SA (Belgium) for future clinical development. For more information, visit

About Anelixis Therapeutics
Anelixis Therapeutics, LLC is a mission-aligned translational medicine and
drug development company created by the ALS Therapy Development Institute in
2013. It uses innovative business models as a virtual biotech to advance
potential ALS treatments, licensed from the Institute and other like-minded
organizations, through early stage clinical development, adding value to the
most promising lead candidates and preparing them for later stage development
together with larger biotechnology and pharmaceutical companies. For more
information, visit or contact 617-599-6514.

About Neurimmune
Neurimmune is a Swiss biotech company focusing on the development of a novel
class of human antibody therapeutics for the treatment and prevention of
severe diseases. Based upon its unique Reverse Translational Medicine™
technology platform, Neurimmune has created a strong and sustainable pipeline
of human antibody programs targeting CNS indications. Neurimmune's business
strategy focuses on the discovery and development of therapeutic antibodies at
early stages of the pharmaceutical value chain and partnering product
candidates for later-stage development and marketing. Neurimmune's lead
program for Alzheimer's disease is partnered with Biogen Idec and currently in
Phase 1b clinical testing. For additional information, please

Media Contact:
Rob Goldstein

SOURCE ALS Therapy Development Institute

Press spacebar to pause and continue. Press esc to stop.